25th Annual Southwest Prostate Cancer Symposium 2020
This Symposium will educate the attendees about advances in the management of localized and advanced prostate cancer, with a focus on imaging, technology, and training in the related devices.
The goal of this educational program is to equip urologists, radiation oncologists, medical oncologists, and other healthcare professionals involved in prostate cancer care with the up-to-date clinical knowledge and tools they need to best treat their patients. The program aims to provide a technical update on all aspects of diagnosis and treatment of localized and advanced disease.
This program also offers training sessions for healthcare professionals to become proficient in imaging, scanning, and prostate cancer treatment-related devices on site.
Keywords: Prostate, Cancer
- Radiation Oncologists
- Medical Oncologists
- Other healthcare professionals
Participants who engage in this educational intervention will be able to:
- Assess which diagnostic tests help distinguish a lower versus higher-risk patient
- Recognize how the decrease in early detection has resulted in prostate cancers presenting at a more advanced stage
- Describe technical advances, including robotic radical prostatectomy, image-guided external beam radiotherapy (IGRT), proton beam therapy, hypofractionated radiotherapy (SBRT), computer-guided brachytherapy, and mpMRI, and demonstrate their role in prostate cancer treatment and detection
- Identify appropriate patients for radiation-based treatments such as brachytherapy, brachytherapy boost, IMRT/IGRT, proton therapy robotic and open prostatectomy, and focal therapy taking serum and genetic influences into account
- Assess the implications of local failure after radiation therapy and introduce new radio-protective technologies
- Discuss treatment of advanced disease, specifically in the non-metastatic CRPC disease state
- Contribute to group discussions regarding potential future research directions to address how we can improve inter-observer agreement and overall quality, develop machine-learning techniques, and improve current technology for staging high-risk disease and for disease monitoring after therapy.
Saturday, December 12, 2020
8:00AM - 12:15PM CME Sessions
Session 1 - Identifying Candidates for Focal Therapy https://us02web.zoom.us/j/85676853505
Session 2 - Limiting Radiation Injury https://live.remo.co/e/2020-virtual-southwest-prostate-
Green Room/Help: https://us02web.zoom.us/j/89732043843
Supported by: Astellas/Pfizer, Boston Scientific, Janssen Biotech, & Sun Pharma
Nelson N. Stone, MD
Professor of Urology and Radiation Oncology
Icahn School of Medicine at Mount Sinai
CEO and President of 3D Biopsy, Inc., New York, New York
Richard G. Stock, MD
Professor of Radiation Oncology
Director of Genito-Urinary Radiation Oncology
Icahn School of Medicine at Mount Sinai, New York, New York
Andre L. deCastro, MD
Keck School of Medicine at USC, Los Angeles, CA
Matthew J. Allaway, DO Perineologic, Inc., Cumberland, MD
Gerald Andriole, Jr., MD
Washington University School of Medicine, St. Louis, MO
Ketan K. Bandani, MD
Icahn School of Medicine at Mount Sinai, New York, NY
Seth R. Blacksburg, MD, MBA
NYU Winthrop Hospital New York, NY
Alan H. Bryce, MD
University of Colorado, Denver,Aurora, CO
Raoul S. Concepcion, MD
The Comprehensive Prostate Center, Nashville, TN
Jason A. Efstathiou, MD
D Phil, Massachusetts General Hospital, Boston, MA
Steven E. Finkelstein, MD
FACRO, Florida Cancer Affiliates/The US Oncology Network Panama City, FL
M. Scott Lucia, MD
University of Colorado, Denver, Aurora, CO
Patric W. Mclaughlin, MD
University of Michigan School of Medicine, Ann Arbor, MI
William K. Oh, MD
The Tisch Cancer Institute, New York, NY
Peter F. Orio III, DO Dana-Farber/Brigham and Womens's Cancer Center, Boston, MA
John F. Ward, MD, FACS The UT M.D. Anderson Cancer Center, Houston, TX
Disclosure of Conflicts of Interest
It is the policy of Medical College of Wisconsin to insure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MCW identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MCW to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.
In accordance with the ACCME® Standards for Commercial Support Six, all in control of content must disclose any relevant financial relationships. The following in control of content had no relevant financial relationships to disclose.
- The employees of Carden Jennings Publishing Medical Communications have no financial relationships to disclose.
In accordance with the ACCME® Standards for Commercial Support Six, all in control of content must disclose any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Medical College of Wisconsin, Carden Jennings Publishing, or the program supporters.
ACCME Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical College of Wisconsin (MCW) and Carden Jennings Publishing Co., Ltd. (CJP). The Medical College of Wisconsin (MCW) is accredited by ACCME to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 4.25 hours of participation for continuing education for allied health professionals.
- 4.25 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 4.25 Hours of ParticipationHours of Participation credit.
Accuray, Astellas/Pfizer, Bayer, Blue Earth, Foundation Medicine, Hitachi, IsoAid, IsoRay, Janssen Biotech, Koelis, Perineologic, Progenics, Retrophin, Sun Pharma